A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Registration Number
- NCT06717347
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1046
- Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues
- Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale
- Has received no prior treatment for their DLBCL
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization
- Has an ejection fraction ≥45% as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA)
- Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)
- Who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
- Has a history of transformation of indolent disease to DLBCL
- Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma
- Has Ann Arbor Stage I DLBCL
- Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication
- Has clinically significant pericardial or pleural effusion
- Has ongoing Grade >1 peripheral neuropathy
- Has a demyelinating form of Charcot-Marie-Tooth disease
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has ongoing corticosteroid therapy
- Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
- Known additional malignancy that is progressing or has required active treatment within the past 2 years
- Known active central nervous system (CNS) lymphoma
- Has active autoimmune disease that has required systemic treatment in the past 2 years
- Has active infection requiring systemic therapy
- Has concurrent active HBV (defined as HBsAg positive and detectable HBV DNA) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection
- Has history of allogeneic tissue/solid organ transplant
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP) Zilovertamab vedotin Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP) Rituximab Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP) Cyclophosphamide Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP) Doxorubicin Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP) Rituximab Biosimilar Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP) Prednisone Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP) Prednisolone Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP) Rescue medication Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Rituximab Participants receive 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar, 1.4 mg/m\^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Cyclophosphamide Participants receive 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar, 1.4 mg/m\^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Doxorubicin Participants receive 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar, 1.4 mg/m\^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Rituximab Biosimilar Participants receive 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar, 1.4 mg/m\^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Prednisone Participants receive 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar, 1.4 mg/m\^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Prednisolone Participants receive 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar, 1.4 mg/m\^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Vincristine Participants receive 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar, 1.4 mg/m\^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months). Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months).
- Primary Outcome Measures
Name Time Method Progression-free survival (PFS) Up to ~ 50 months PFS is defined as the time from randomization to the first documented disease progression per Lugano response criteria by blinded independent central review (BICR) or death due to any cause, whichever occurs first.
- Secondary Outcome Measures
Name Time Method Complete Response at End of Treatment (CR at EOT) Up to ~ 32 months CR at EOT is defined as a CR per Lugano response criteria as assessed by BICR at end of treatment. Participants with missing data or who discontinue treatment or study prior to reaching EOT will be considered non-responders and included in the total number of participants.
Overall Survival (OS) Up to ~ 74 months OS is defined as the time from randomization to death due to any cause.
Event-free Survival (EFS) Up to ~ 74 months EFS is defined as the time from randomization to any of the following events: progressive disease that precludes surgery, local or distant recurrence, second primary malignancy or death due to any cause. The EFS for all participants will be presented.
Duration of Complete Response (DurCR) Up to ~ 74 months For participants who demonstrate CR at EOT per Lugano response criteria by BICR, duration of complete response is defined as the time from the first documented evidence of CR at or before EOT until disease progression or death due to any cause, whichever occurs first.
Number of Participants Who Experience an Adverse Event (AE) Up to ~ 9 months An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be presented.
Number of Participants Who Discontinue Study Treatment Due to an AE Up to ~ 6 months An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.
Change From Baseline in Health-Related Quality Of Life (HRQoL) on Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Trial Outcome Index (TOI) Score Baseline and Week 25 The FACT-Lym is a 42-item questionnaire designed to measure HRQoL and cancer-specific symptoms in non-Hodgkin lymphoma patients. Subscales include FACT-General (FACT-G), FACT-Trial Outcome Index (FACT-TOI), FACT-Lym total score (FACT-Lym TS), and the Lymphoma subscale (Lym S). The Lym S has a single domain consisting of 15 items specific to lymphoma burden with a score ranging from 0 to 60. FACT-G has 4 well-being domains, physical (7 items), social/family (7), emotional (6), and functional (7), with scores ranging from 0 to 108. FACT-TOI combines FACT-G's physical and functional domains with Lym S, with scores ranging from 0 to 116. FACT-Lym TS combines FACT-G with Lym S, with scores ranging from 0 to 168. The scoring of FACT-Lym is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. The higher the score the better the quality of life.
Change From Baseline in HRQoL on FACT-Lym Total Score Baseline and Week 25 The FACT-Lym is a 42-item questionnaire designed to measure HRQoL and cancer-specific symptoms in non-Hodgkin lymphoma patients. Subscales include FACT-General (FACT-G), FACT-Trial Outcome Index (FACT-TOI), FACT-Lym total score (FACT-Lym TS), and the Lymphoma subscale (Lym S). The Lym S has a single domain consisting of 15 items specific to lymphoma burden with a score ranging from 0 to 60. FACT-G has 4 well-being domains, physical (7 items), social/family (7), emotional (6), and functional (7), with scores ranging from 0 to 108. FACT-TOI combines FACT-G's physical and functional domains with Lym S, with scores ranging from 0 to 116. FACT-Lym TS combines FACT-G with Lym S, with scores ranging from 0 to 168. The scoring of FACT-Lym is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. The higher the score the better the quality of life.
Change From Baseline in HRQoL on FACT-Lym Physical Wellbeing (PWB) Score Baseline and Week 25 The FACT-Lym is a 42-item questionnaire designed to measure HRQoL and cancer-specific symptoms in non-Hodgkin lymphoma patients. Subscales include FACT-General (FACT-G), FACT-Trial Outcome Index (FACT-TOI), FACT-Lym total score (FACT-Lym TS), and the Lymphoma subscale (Lym S). The Lym S has a single domain consisting of 15 items specific to lymphoma burden with a score ranging from 0 to 60. FACT-G has 4 well-being domains, physical (7 items), social/family (7), emotional (6), and functional (7), with scores ranging from 0 to 108. FACT-TOI combines FACT-G's physical and functional domains with Lym S, with scores ranging from 0 to 116. FACT-Lym TS combines FACT-G with Lym S, with scores ranging from 0 to 168. The scoring of FACT-Lym is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. The higher the score the better the quality of life.
Change From Baseline in HRQoL on Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) Neurotoxicity Subscale Score Baseline and Week 25 The FACT GOG-NTX provides a targeted assessment of symptoms of peripheral neuropathy, including sensory, motor, and auditory problems and cold sensitivity. It is an 11-item questionnaire designed to measure the neurotoxicity subscale. The scoring of FACT GOG-NTX is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. To produce a Neurotoxicity Subscale score (range 0-44), multiply the sum of the item scores by the number of items in the subscale, then divide by the number of items answered.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (123)
Cancer Blood and Specialty Clinic ( Site 0109)
🇺🇸Los Alamitos, California, United States
Cancer Care Specialists of Illinois ( Site 0152)
🇺🇸O'Fallon, Illinois, United States
Fort Wayne Medical Oncology and Hematology ( Site 0149)
🇺🇸Fort Wayne, Indiana, United States
Cotton O'Neil Cancer Center ( Site 0108)
🇺🇸Topeka, Kansas, United States
Truman Medical Center ( Site 0122)
🇺🇸Kansas City, Missouri, United States
OptumCare Cancer Care ( Site 0121)
🇺🇸Las Vegas, Nevada, United States
Comprehensive Cancer Centers of Nevada ( Site 0113)
🇺🇸Las Vegas, Nevada, United States
New York Oncology Hematology, P.C. ( Site 0129)
🇺🇸Albany, New York, United States
University of Virginia Cancer Center ( Site 0138)
🇺🇸Charlottesville, Virginia, United States
Virginia Cancer Institute ( Site 0148)
🇺🇸Richmond, Virginia, United States
Blue Ridge Cancer Care ( Site 0132)
🇺🇸Roanoke, Virginia, United States
SSM Health Dean Medical Group ( Site 0140)
🇺🇸Madison, Wisconsin, United States
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0306)
🇦🇷Mar del Plata, Buenos Aires, Argentina
Fundacion Estudios Clinicos ( Site 0311)
🇦🇷Rosario., Santa Fe, Argentina
Hospital Italiano de Buenos Aires ( Site 0304)
🇦🇷Caba, Argentina
ASBL CHU Helora - Hôpital de Mons - Site Kennedy ( Site 1103)
🇧🇪Mons, Hainaut, Belgium
Hospital Erasto Gaertner ( Site 0401)
🇧🇷Curitiba, Parana, Brazil
Liga Norte Riograndense Contra o Cancer ( Site 0407)
🇧🇷Natal, Rio Grande Do Norte, Brazil
CEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina ( Site 0403)
🇧🇷Florianópolis, Santa Catarina, Brazil
Hope ( Site 0413)
🇧🇷Ribeirao Preto, Sao Paulo, Brazil
Clinica Advanze ( Site 0411)
🇧🇷Sao Carlos, Sao Paulo, Brazil
F. F. R. M. São Jose do Rio Preto ( Site 0404)
🇧🇷Sjrp, Sao Paulo, Brazil
Biocenter ( Site 0510)
🇨🇱Concepcion., Biobio, Chile
Centro de Estudios Clínicos SAGA ( Site 0508)
🇨🇱Santiago, Region M. De Santiago, Chile
Beijing Cancer Hospital ( Site 3101)
🇨🇳Beijing, Beijing, China
Chongqing Cancer Hospital ( Site 3113)
🇨🇳Chongqing, Chongqing, China
Fujian Provincial Cancer Hospital. ( Site 3119)
🇨🇳Fuzhou, Fujian, China
Zhujiang Hospital of Southern Medical University ( Site 3122)
🇨🇳Guangzhou, Guangdong, China
Affiliated Cancer Hospital of Guangxi Medical University ( Site 3123)
🇨🇳Nanning, Guangxi, China
The Affiliated Hospital of Guizhou Medical University ( Site 3112)
🇨🇳Guiyang, Guizhou, China
Hubei Cancer Hospital ( Site 3125)
🇨🇳Wuhan, Hubei, China
Affiliated Hospital of Nantong University ( Site 3117)
🇨🇳Nantong, Jiangsu, China
Jiangxi Cancer Hospital ( Site 3118)
🇨🇳Nanchang, Jiangxi, China
Shandong Cancer Hospital ( Site 3108)
🇨🇳Jinan, Shandong, China
Sichuan Cancer Hospital. ( Site 3111)
🇨🇳Chengdu, Sichuan, China
West China Hospital, Sichuan University ( Site 3110)
🇨🇳Chengdu, Sichuan, China
Institute of Hematology and Blood Diseases Hosp CAMS&PUMC ( Site 3105)
🇨🇳Tianjin, Tianjin, China
Yunnan Province Cancer Hospital ( Site 3109)
🇨🇳Kunming, Yunnan, China
The First Affiliated Hospital, Zhejiang Medical University ( Site 3116)
🇨🇳Hangzhou, Zhejiang, China
Hospital Pablo Tobon Uribe ( Site 0604)
🇨🇴Medellin, Antioquia, Colombia
IMAT S.A.S ( Site 0603)
🇨🇴Montería, Cordoba, Colombia
Hospital Universitario San Ignacio ( Site 0607)
🇨🇴Bogota., Distrito Capital De Bogota, Colombia
Oncologos del Occidente ( Site 0601)
🇨🇴Pereira., Risaralda, Colombia
Fundación Valle del Lili ( Site 0602)
🇨🇴Cali, Valle Del Cauca, Colombia
Aalborg University Hospital ( Site 1302)
🇩🇰Aalborg, Nordjylland, Denmark
CHU Dijon Bourgogne ( Site 1516)
🇫🇷Dijon, Cote-d Or, France
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 1512)
🇫🇷Limoges, Limousin, France
Centre Hospitalier Régional Metz Thionville - Hôpital de Mercy ( Site 1515)
🇫🇷Metz, Moselle, France
Centre Hospitalier de Dunkerque ( Site 1513)
🇫🇷Dunkerque, Nord, France
Centre Hospitalier de la Cote Basque ( Site 1509)
🇫🇷Bayonne, Pyrenees-Atlantiques, France
HIA Sainte Anne ( Site 1506)
🇫🇷Toulon, Var, France
Centre Hospitalier d'Avignon ( Site 1505)
🇫🇷Avignon, Vaucluse, France
CHD Vendee ( Site 1502)
🇫🇷La Roche-sur-Yon, Vendee, France
CELAN,S.A ( Site 0702)
🇬🇹Guatemala., Guatemala
MEDI-K ( Site 0701)
🇬🇹Guatemala, Guatemala
Cen Integral Onco Gastro y Hemato Onco Guatemala S.A. ( Site 0703)
🇬🇹Guatemala, Guatemala
Princess Margaret Hospital ( Site 3202)
🇭🇰Hong Kong, Hong Kong
Queen Mary Hospital ( Site 3201)
🇭🇰Hong Kong, Hong Kong
Carmel Hospital ( Site 1903)
🇮🇱Haifa, Israel
Hadassah Medical Center ( Site 1901)
🇮🇱Jerusalem, Israel
Sourasky Medical Center ( Site 1904)
🇮🇱Tel Aviv, Israel
Poria Medical Center ( Site 1902)
🇮🇱Tiberias, Israel
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia ( Site 2010)
🇮🇹Candiolo, Torino, Italy
AOU delle Marche Ospedali Riuniti di Ancona ( Site 2011)
🇮🇹Ancona, Italy
IEO Istituto Europeo di Oncologia ( Site 2009)
🇮🇹Milano, Italy
Ospedale Santa Maria delle Croci ( Site 2006)
🇮🇹Ravenna, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore (
🇮🇹Roma, Italy
Nagoya University Hospital ( Site 3309)
🇯🇵Nagoya, Aichi, Japan
National Hospital Organization Shikoku Cancer Center ( Site 3321)
🇯🇵Matsuyama, Ehime, Japan
Kobe City Medical Center General Hospital ( Site 3318)
🇯🇵Kobe, Hyogo, Japan
Kanazawa University Hospital ( Site 3308)
🇯🇵Kanazawa, Ishikawa, Japan
Tokai University Hospital ( Site 3302)
🇯🇵Isehara, Kanagawa, Japan
Tohoku University Hospital ( Site 3301)
🇯🇵Sendai, Miyagi, Japan
Kindai University Hospital ( Site 3310)
🇯🇵Osakasayama, Osaka, Japan
Saitama Medical University Hospital ( Site 3305)
🇯🇵Iruma-gun, Saitama, Japan
Juntendo University Hospital ( Site 3307)
🇯🇵Bunkyo, Tokyo, Japan
University of Yamanashi Hospital ( Site 3320)
🇯🇵Chuo, Yamanashi, Japan
Chiba Cancer Center ( Site 3314)
🇯🇵Chiba, Japan
Kyushu University Hospital ( Site 3313)
🇯🇵Fukuoka, Japan
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 3322)
🇯🇵Hiroshima, Japan
University Hospital,Kyoto Prefectural University of Medicine ( Site 3315)
🇯🇵Kyoto, Japan
University of Miyazaki Hospital ( Site 3319)
🇯🇵Miyazaki, Japan
Okayama University Hospital ( Site 3311)
🇯🇵Okayama, Japan
Osaka Metropolitan University Hospital ( Site 3317)
🇯🇵Osaka, Japan
Yamagata University Hospital ( Site 3312)
🇯🇵Yamagata, Japan
National Cancer Center- Center for Hemotologic malignancy ( Site 3806)
🇰🇷Goyang-si, Kyonggi-do, Korea, Republic of
Pusan National University Hospital ( Site 3804)
🇰🇷Busan, Pusan-Kwangyokshi, Korea, Republic of
Chungnam National University Hospital ( Site 3801)
🇰🇷Daejeon, Taejon-Kwangyokshi, Korea, Republic of
Severance Hospital, Yonsei University Health System ( Site 3802)
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center ( Site 3807)
🇰🇷Seoul, Korea, Republic of
St.Mary's H., Youido ( Site 3805)
🇰🇷Seoul, Korea, Republic of
Queen Elizabeth Hospital ( Site 3405)
🇲🇾Kota Kinabalu, Sabah, Malaysia
Hospital Miri ( Site 3403)
🇲🇾Miri, Sarawak, Malaysia
Meander Medisch Centrum ( Site 2101)
🇳🇱Amersfoort, Utrecht, Netherlands
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2201)
🇵🇱Warszawa, Mazowieckie, Poland
Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 2210)
🇵🇱Słupsk, Pomorskie, Poland
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2208)
🇵🇱Gliwice, Slaskie, Poland
Pratia Onkologia Katowice ( Site 2204)
🇵🇱Katowice, Slaskie, Poland
Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko
🇵🇱Olsztyn, Warminsko-mazurskie, Poland
BRCR Global - Mayaguez ( Site 1003)
🇵🇷Mayaguez, Puerto Rico
Auxilio Mutuo Cancer Center ( Site 1001)
🇵🇷San Juan, Puerto Rico
Institutul Oncologic Cluj ( Site 2404)
🇷🇴Cluj-Napoca, Cluj, Romania
Spital Judetean Sibiu ( Site 2405)
🇷🇴Sibiu, Romania
National Cancer Centre Singapore ( Site 3701)
🇸🇬Singapore, Central Singapore, Singapore
Hospital Universitario Virgen Macarena ( Site 2608)
🇪🇸Sevilla, Andalucia, Spain
H. Insular de Gran Canaria ( Site 2606)
🇪🇸Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital General Universitario Dr. Balmis ( Site 2604)
🇪🇸Alicante, Valenciana, Comunitat, Spain
Hospital del Mar ( Site 2610)
🇪🇸Barcelona, Spain
Hospital Universitario La Paz ( Site 2611)
🇪🇸Madrid, Spain
Hospital Virgen de la Victoria ( Site 2609)
🇪🇸Malaga, Spain
Ospedale Regionale Bellinzona e Valli ( Site 2701)
🇨🇭Bellinzona, Ticino, Switzerland
National Cheng Kung University Hospital ( Site 3902)
🇨🇳Tainan, Taiwan
Mackay Memorial Hospital ( Site 3908)
🇨🇳Taipei, Taiwan
National Taiwan University Hospital ( Site 3901)
🇨🇳Taipei, Taiwan
Tri-Service General Hospital ( Site 3906)
🇨🇳Taipei, Taiwan
Chang Gung Memorial Hospital - Linkou Branch ( Site 3903)
🇨🇳Taoyuan, Taiwan
MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( S
🇺🇦Cherkasy, Cherkaska Oblast, Ukraine
Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Si
🇺🇦Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine
Khmelnytskyi Regional Hospital ( Site 2907)
🇺🇦Khmelnytskiy, Khmelnytska Oblast, Ukraine
Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2903)
🇺🇦Lviv, Lvivska Oblast, Ukraine
SNPE National Cancer Institute ( Site 2902)
🇺🇦Kyiv, Ukraine
Universal Clinic Oberig ( Site 2908)
🇺🇦Kyiv, Ukraine
Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co
🇺🇦Kyiv, Ukraine